Ann: Pre-Submission package lodged with the US FDA, page-42

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 42 Last

Share
Profile

Follow
AlCp

27,899 Posts.

1797

10/02/21

23:35

Post #: 50878679
Share

Originally posted by Yenom23 ↑

looks like even if they get through the pre- submission phase with the FDA, and then the time it takes to throw questions back and forth, the final submission, if it gets that far, won’t be ready by at least the end of calendar year 2021. That’s if they don’t need more studies done and then it’s just up in the air as to how long that takes and whether it has a chance of getting up in a timeframe where shareholders are diluted to buggery.

so what positive catalysts can actually eventuate to get the price moving forward again before the inevitable next capital raising ??

Rap share price has been hit to below 7c on decent volume, it has tried to bounce twice in the past week which has been met with more selling pressure, sucking in another round of buyers, but decreasing numbers of them as there becomes less and less people willing to believe the BS. I think this will be the pattern from now on, but with lower lows and lower highs. This is how over hyped stocks trade whilst they wind right back to being a shell company, where incidentally, RAP actually started.
I feel sorry for all of you who have lost money.
The management has over hyped the opportunity and grossly misled the market on what they purported they could could achieve with this tech imho.

I remember for years rap went to every retail investor conference and shouted from the rooftops with reckless confidence that they were the next massive thing in digital health.
They convinced many retail comSec traders and even pulled the wool-over the morgans analysts who dragged along their corporate department to flog cap raises to their network of brokers and their clients.

what managment has promised has been a load of BS imho and the fact NONE of them have bought on market (or at all), unlike many of you here, this just says it all - if you can’t see that It’s something you should ponder as they still draw a wage, TK gets 10m free shares and shareholders just cop it sweet.

there are alternatives to play in this amazing space and achieve the upside that the sector has to offer. I have been through this with other companies but now I just back capable managment that actually have a track record of delivery and who are currently delivering.

Imho DYOR on the leaders in the digital respiratory health space and cut your losses on companies with managment that are not only inept but who are also taking the piss out of shareholders.

Expand

Excellent clinic evaluation results which will start to generate revenue of ResAppDx into this sector and Medgate signing up as the first telehealth provider in Europe, these are all due in 3 months and push the pps back to 20c IMO.
RAP is a very unique product which doesn't have any technology limitation since this is totally objective so the doctors can't do what the product does. Hence, there are no other alternate stock in this sector which RAP provide, especially one that has all age demographic market which mean a massive revenue potential covering all the medical field in telehealth, clinic and ED and later DTC.

Last edited by AlCp: 10/02/21

RAP Price at posting: 6.8¢ Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

CLE

Cyclone signs MOU with Vale for development of Iron Bear play

BNL

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

HotCopper Highlights: Your most watched stocks for Week 46, 2024

GDM

Banshee's historic trenches prove rich in antimony and gold for GDM

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

EEG

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

CUF

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

IRX

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

First 42 Last

Add RAP (ASX) to my watchlist

Ann: Pre-Submission package lodged with the US FDA, page-42

Top Stories

Cyclone signs MOU with Vale for development of Iron Bear play

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

HotCopper Highlights: Your most watched stocks for Week 46, 2024

Banshee's historic trenches prove rich in antimony and gold for GDM

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Featured News